BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target

Denali Therapeutics, Inc. (NASDAQ:DNLI) is one of the best oversold NASDAQ stocks to buy now. In a report released on July 7, Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics, Inc. (NASDAQ:DNLI) with a price target of $32.00.

Basing the optimistic rating on the company’s promising developments, the analyst reasoned that Denali Therapeutics, Inc. (NASDAQ:DNLI) has made notable developments in its enzyme replacement therapy, DNL-310, which the FDA has accepted for priority review for the treatment of Hunter Syndrome.

He stated that therapy is significant for its ability to cross the blood-brain barrier, which may provide considerable advantages over the present treatments. With the FDA’s acceptance showing strong regulatory support, the drug may attain an expedited path to the market.

The firm also stated that Denali Therapeutics, Inc.’s (NASDAQ:DNLI) broader pipeline, which includes other Transport Vehicle-enabled therapies, also suggests the potential to address various neurological conditions.

Denali Therapeutics, Inc. (NASDAQ:DNLI) develops and commercializes product candidates for the treatment of neurodegenerative diseases. Its product portfolio includes LRRK2, RIPK1, TREM2, and Tau.

While we acknowledge the potential of DNLI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.